Pacer Advisors
RIGL icon

Pacer Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Pacer Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37M Sell
86,146
-28,240
-25% -$871K 0.01% 823
2026
Q1 		$3.09M Buy
114,386
+48,882
+75% +$1.64M 0.01% 767
2025
Q4 		$2.81M Sell
65,504
-11,976
-15% -$451K 0.01% 921
2025
Q3 		$2.2M Buy
+77,480
New +$2.32M 0.01% 1015
2025
Q2 		– Sell
-112,629
Closed -$2.03M – 3563
2025
Q1 		$2.03M Buy
+112,629
New +$2.29M ﹤0.01% 943
2021
Q2 		– Sell
-1,464
Closed -$50K – 1534
2021
Q1 		$50K Buy
1,464
+199
+16% +$7.88K ﹤0.01% 1436
2020
Q4 		$44K Buy
+1,265
New +$36.6K ﹤0.01% 1427
2018
Q4 		– Sell
-1,924
Closed -$62K – 938
2018
Q3 		$62K Buy
+1,924
New +$57.8K ﹤0.01% 1130

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's RIGL Position: Q2 2026 in Review

Pacer Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 25% in Q2 2026, selling an estimated $871K and leaving 86,146 shares worth $3.37M. The position accounts for 0.01% of the portfolio, ranked #823.

Pacer Advisors first reported a position in RIGL in Q3 2018 and has held it in 8 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Pacer Advisors held 86,146 shares of Rigel Pharmaceuticals worth $3.37M as of Q2 2026.
  • Pacer Advisors sold 28,240 Rigel Pharmaceuticals shares in Q2 2026, an estimated $871K.
  • Rigel Pharmaceuticals made up 0.01% of Pacer Advisors's portfolio in Q2 2026, its #823 holding.
  • Pacer Advisors first reported a position in Rigel Pharmaceuticals in Q3 2018 and has held it in 8 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.